DNA Sequencing Market: Opportunities and Future Scope from 2025 to 2032 | Thermo Fisher Scientific, Inc. and Illumina

The DNA Sequencing Market is a critical sector driving innovations across genomics, personalized medicine, and biotechnology industries. With advancements in next-generation sequencing (NGS) technologies and decreasing costs, the industry has witnessed accelerated adoption in clinical diagnostics, agricultural genomics, and pharmaceutical research. Increasing demand for precision medicine and the rise in genetic disorder testing are catalyzing rapid expansion. The Global DNA Sequencing Market size is estimated to be valued at USD 8,486.7 Mn in 2025 and is expected to reach USD 18,412.4 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.7% from 2025 to 2032.

➔ Request a sample Report Now to explore the full potential: https://www.coherentmarketinsights.com/insight/request-sample/5531

➤Actionable Insights

● The surge in adoption of high-throughput sequencing platforms has directly influenced the market size of DNA sequencing, with Illumina's NovaSeq platform alone accounting for over 40% of total sequencing output in 2024, facilitating broader clinical and research applications.
● Pricing dynamics indicate a steady decline in per-genome sequencing costs, which fell below USD 600 in 2024 compared to over USD 1,000 in 2022, enabling wider accessibility across emerging economies and expanding market revenue substantially.
● Export volumes of sequencing reagents and consumables increased by 15% year-over-year in 2025, indicating robust supply chain scalability, particularly from North American and European manufacturing hubs.
● Diverse use cases, including oncology, inherited disease diagnostics, and agricultural genomics, drove demand, with oncology-related sequencing services growing by 22% in 2024, highlighting the strategic importance of clinical applications in market growth strategies.

➤Market Segment and Regional Coverage

● By Technology: Next-Generation Sequencing (NGS), Sanger Sequencing, Third-Generation Sequencing, and Others
● By Application: Clinical Diagnostics, Academic Research, Agriculture & Animal Research, Forensics, and Others
● By End User: Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research Centers, and Others
Regional and Country Analysis:
● North America: U.S. and Canada
● Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
● Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
● Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
● Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA

➔ Elevate your business strategy with comprehensive market data. Request a sample report now: https://www.coherentmarketinsights.com/insight/request-sample/5531

➤Key Players

● Thermo Fisher Scientific, Inc.
● Illumina, Inc.
● PerkinElmer Genomics
● QIAGEN
● Agilent Technologies, Inc.
● F. Hoffmann-La Roche Ltd
● Macrogen, Inc.
● Abbott
● PacBio
● Zymo Research Corporation
● Oxford Nanopore Technologies plc
● Tecan Trading AG
● Hamilton Company
● ZS Genetics, Inc.
● LI-COR, Inc.
● Competitive strategies in the DNA sequencing market include Illumina's aggressive expansion in NGS platforms to maintain market share, resulting in a 12% increase in global installations in 2024. Thermo Fisher Scientific's strategic acquisition of complementary genomics companies has enhanced its service portfolio, boosting revenue by 18% in 2025. Meanwhile, Oxford Nanopore Technologies has focused on portable sequencing solutions, expanding adoption in field-based genomics, particularly in emerging markets such as India and Brazil.

➤Growth factors

● Increasing prevalence of genetic disorders and rising investments in genomics research are key drivers, with global government funding for precision medicine initiatives surpassing USD 1.5 billion in 2024.
● Technological innovations lowering sequencing costs and improving data throughput continue to foster market growth, evidenced by a 25% increase in sequencing capacity globally from 2023 to 2025.
● Expansion of clinical applications, particularly in oncology and rare diseases, is driving demand, with clinical sequencing services contributing over 45% of total market revenue in 2025.

➔ Get Instant Access! Purchase Research Report and receive a 25% Discount: https://www.coherentmarketinsights.com/insight/buy-now/5531

➤ Market Trends

● The rise of third-generation sequencing technologies providing longer read lengths is reshaping market dynamics, with PacBio and Oxford Nanopore collectively growing their market share by 30% in 2024.
● Integration of AI and machine learning algorithms in sequencing data analysis is a notable trend, enhancing accuracy and reducing turnaround times by approximately 20%, thus improving operational efficiencies.
● Increasing collaboration between sequencing companies and pharmaceutical firms is driving co-development of companion diagnostics, accelerating drug discovery timelines by 15% on average.

➤Market Opportunities

● By Application: Clinical diagnostics segment holds significant opportunities due to expanding adoption of liquid biopsy techniques, projected to grow at a CAGR of 14.3% from 2025 to 2032.
● By Technology: Next-Generation Sequencing (NGS) continues to offer growth potential, supported by increasing investments in automation and miniaturization of sequencing platforms.
● By End User: Pharmaceutical and biotechnology companies are expanding R&D activities, with genomics-driven drug development expected to contribute 35% of total market revenue by 2030.
● Regional Opportunity: Asia Pacific presents a lucrative opportunity driven by increasing government support for genomic initiatives and growing healthcare infrastructure, with market revenue anticipated to grow at over 13% CAGR during the forecast period.

❓ Frequently Asked Questions

1. Who are the dominant players in the DNA Sequencing Market?
The market is dominated by leading companies such as Thermo Fisher Scientific, Illumina, PerkinElmer Genomics, QIAGEN, and Agilent Technologies, which collectively hold a significant industry share through technological innovation and strategic partnerships.

2. What will be the size of the DNA Sequencing Market in the coming years?
The DNA Sequencing Market size is projected to reach USD 18,412.4 Mn by 2032, growing at a CAGR of 11.7% from 2025 to 2032, driven by expanding clinical and research applications.

3. Which end-user industry has the largest growth opportunity?
Clinical diagnostics is the largest growth segment, with increasing demand for genetic testing in oncology and rare diseases, contributing to more than 45% of the market revenue in 2025.

4. How will market development trends evolve over the next five years?
Market trends indicate a shift toward third-generation sequencing technologies, AI-enabled data analysis, and enhanced collaboration between sequencing firms and pharmaceutical companies to accelerate drug discovery and diagnostics.

5. What is the nature of the competitive landscape and challenges in the DNA Sequencing Market?
The competitive landscape is characterized by rapid innovation, aggressive pricing strategies, and mergers and acquisitions. Challenges include data management complexities and regulatory compliance across different geographies.

6. What go-to-market strategies are commonly adopted in the DNA Sequencing Market?
Key strategies include technology partnerships, expansion of product portfolios, regional market penetration, and investment in R&D to improve sequencing accuracy and reduce costs, thereby increasing market share and business growth.
This comprehensive DNA Sequencing Market report offers deep market insights, including market size, market share, market revenue, market trends, and business growth strategies, aiding experts in making informed decisions and capitalizing on emerging market opportunities.

Author of this marketing PR:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from Openpr her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Contact Us:

Mr. Shah
Coherent Market Insights
533 Airport Boulevard,
Suite 400, Burlingame,
CA 94010, United States
US: + 12524771362
UK: +442039578553
AUS: +61-8-7924-7805
India: +91-848-285-0837

This release was published on openPR.